您的位置: 首页 > 农业专利 > 详情页

Methods for treating cancer with anti-PD-1 antibodies
专利权人:
Merck Sharp & Dohme Corp.
发明人:
LALA, Mallika,JAIN, Lokesh,LI, Mengyao
申请号:
AU2019220495
公开号:
AU2019220495A1
申请日:
2019.02.08
申请国别(地区):
AU
年份:
2020
代理人:
摘要:
The present invention relates to methods for treating cancer in a patient comprising administering a PD-1 antagonist, e.g., an anti-PD-1 antibody or antigen binding fragment thereof (e.g. pembrolizumab), in specific amounts to the patient about every six weeks. In some embodiments, the amount of anti-PD-1 antibody or antigen binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充